NuCana plc (NASDAQ: NCNA) reported a net loss of £3.1 million for the second quarter ended June 30, 2026, a sharp contraction from the £24.1 million loss recorded in the corresponding quarter of 2025. The clinical-stage biopharmaceutical company also announced that its cash position of £19.5 million as of June 30 is expected to fund planned operations through 2029.

The improvement in the bottom line was primarily driven by the absence of significant non-cash finance expenses that impacted the prior year period. For the six months ended June 30, 2026, NuCana reported a net loss of £6.9 million, down from £26.6 million in the same period of 2025. The prior year’s half-year loss included a £12.6 million non-cash loss on the fair value revaluation of warrants issued in May 2025, a charge that did not recur in the current period.

Financial Performance Overview

Operating expenses declined significantly year-over-year, reflecting disciplined cost management alongside pipeline progression. Research and development expenses fell to £2.25 million in Q2 2026 from £7.1 million in Q2 2025. Administrative expenses also dropped to £1.19 million from £4.5 million in the prior year quarter.

Share-based payment expenses decreased to £2.8 million for the first half of 2026, compared to £8.2 million in the first half of 2025. Professional fees related to warrant issuance were nil in the current period, versus £1.4 million in the prior year.

What the Numbers Show

The divergence between the reported net loss and operating loss highlights the impact of non-operational items on NuCana’s financials. In Q2 2025, the operating loss was £11.8 million, but the net loss ballooned to £24.1 million due to a £12.6 million non-cash finance expense related to warrant revaluation. In Q2 2026, with no such finance expense, the net loss (£3.1 million) closely tracked the operating loss (£3.5 million), providing a clearer view of the company’s core operational burn rate. This normalization suggests that the current cash runway calculation is based on sustainable operational costs rather than distorted by one-off fair value adjustments.

Pipeline and Strategic Updates

NuCana highlighted progress in its clinical development program for NUC-7738, an anti-cancer agent that disrupts RNA polyadenylation. The company completed patient recruitment in the Phase 2 expansion study (NuTide:701), which evaluates NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant metastatic melanoma. Final data from this study is expected later in 2026.

Following IND clearance from the US Food and Drug Administration earlier this year, NuCana is engaging with regulators to determine the optimal path for a potential registrational strategy in melanoma. The company is also assessing additional indications and combination strategies for both NUC-7738 and its second pipeline candidate, NUC-3373, a targeted thymidylate synthase inhibitor.

Balance Sheet Position

As of June 30, 2026, total assets stood at £25.8 million, including £19.5 million in cash and cash equivalents. Total liabilities were £5.5 million, comprising trade payables, accrued expenditures, and lease liabilities. The company’s equity attributable to holders was £20.3 million, down from £24.3 million at December 31, 2025, reflecting the accumulated deficit from ongoing operations.